# Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis

> **NCT02219932** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 646 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** fampridine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02219932
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 646 (ACTUAL)
- **Last updated:** 2017-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02219932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02219932, "Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02219932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*